U.S. stock night trading opens with fluctuations: Navitas Semiconductor rises 9.32% in night trading; Zynex falls 8.85% in night trading

U.S. Stock Night Market Opening Movements Navitas Semiconductor rose 9.32% in the night market. Based on recent news, On December 16, Dipender Saluja, a director of Navitas Semiconductor, reported the sale of Class A common stock. This news may raise market attention on insider trading, leading to stock price fluctuations. On December 16, Singh Ranbir, a director of Navitas Semiconductor, submitted Form 4, disclosing that he sold 179,354 shares of the company's stock on December 12 for a transaction amount of $1,556,829. This insider trading information may impact market sentiment. On December 15, Capricorn-Libra Investment Group LP submitted Form 144, planning to sell 873,488 shares of restricted securities of Navitas Semiconductor. This move may raise market concerns about an increase in the supply of the company's stock, affecting the stock price. Analysts rate Navitas Semiconductor as hold. Zynex fell 8.85% in the night market. Based on recent news, On December 16, Zynex announced it filed for Chapter 11 bankruptcy reorganization under the U.S. Bankruptcy Code. The company stated that despite entering bankruptcy proceedings, its operations would continue and remain unaffected. This news led to a significant drop in stock price. On December 16, Zynex's third-quarter financial report showed revenue of only $13.36 million, a decline of over 73% year-on-year, far below the market expectation of $24.53 million. Delays and denials of Tricare-related accounts were the main reasons, further affecting the company's revenue stability. On December 16, Zynex secured $22.3 million in new financing to support its reorganization plan. Nevertheless, market uncertainty about the company's future remains, leading to continued stock price declines. The overall industry performance is weak, with increasing macroeconomic uncertainty. Top Gainers in the U.S. Stock Night Market DBV Technologies rose 61.96% in the night market. Based on recent news, On December 16, DBV Technologies announced that its Phase III clinical trial for treating peanut-allergic children achieved its primary endpoint, causing the stock price to soar nearly 70%. The trial results showed that 46.6% of children treated with its drug candidate VIASKIN responded after twelve months, compared to only 14.8% in the placebo group. The company stated it plans to submit a Biologics License Application in the first half of 2026. On December 15, Cantor Fitzgerald announced a target stock price of $42 per share for DBV Technologies On December 17, DBV Technologies stated that the FDA had previously granted the patch breakthrough therapy designation, and the company expects that the license application may be prioritized for review. The biopharmaceutical industry has performed strongly recently, with investors focusing on the progress of new drug development. Addex Therapeutics rose 15.74% in after-hours trading, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Genenta Science S.P.A. rose 12.12% in after-hours trading, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation